1 Biotech Stock Down 52% That Could Soar by 233%, According to Wall Street
Viking Therapeutics seems to be doubling down on its hopes of making waves in the weight management market as a stand-alone ...
Hims & Hers Has Superstar Potential, But It Will Take A Lot To Get There
Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...
News Medical on MSN10h
Healthcare groups urge FDA to act on compounding regulations after GLP-1 medicine shortages
Today, the Obesity Action Coalition (OAC) and The Obesity Society (TOS) sent a letter to the U.S. Food & Drug Administration (FDA), along with more than 20 leading organizations and providers across ...
Northcountrypublicradio.org3d
Patients scramble as cheaper obesity drug alternatives disappear
Compounding pharmacies have been allowed to essentially make a cheaper version of Eli Lilly's Zepbound, but they have to stop Wednesday. That's... Patients scramble as cheaper obesity drug ...
Benzinga.com5d
Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?
Eli Lilly & Co. LLY launched its own GLP-1/GIP dual agonist treatment for obesity, Zepbound, in December 2023. Zepbound is the most effective FDA-approved GLP-1 drug for weight loss. Between Novo ...
Benzinga.com2d
STAT+: Tapping the potential of GLP-1 drugs requires integrated care and overcoming inequities, executives say
a major telehealth platform that recently struck a deal with Lilly for its obesity medication Zepbound.